Pre-Register for an Internet Symposium on April 5th, 6th, or 7th

[Guest guest]

Having trouble viewing this email? Click here

Program Dates and Times

April 5, 2011 - 16:00 GMT (Noon EDT) - CLICK HERE TO REGISTER

April 6, 2011 - 18:00 GMT (14:00 PM EDT) - CLICK HERE TO REGISTER

April 7, 2011 - 23:00 GMT (19:00 PM EDT) - CLICK HERE TO REGISTER

This 1.5-hour Internet symposium will review and discuss the key studies on

chronic hepatitis C management and treatment presented at EASL. The symposium

will feature four well-known and recognized thought leaders in the HCV field,

with three serving as presenting faculty/discussants and one as program

moderator. This activity has been designed to meet the educational needs of

physicians involved in the care of patients with chronic hepatitis C infection.

This program is certified for CME credit for US physicians by the Postgraduate

Institute for Medicine.

Course Director and Moderator

Mark Sulkowski, MD

Associate Professor of Medicine and Medical Director,

Viral Hepatitis Center,

s Hopkins University School of Medicine

Baltimore, land

Faculty:

Nezam H. Afdhal, MD

Associate Professor of Medicine,

Harvard School of Medicine

Chief of Hepatology, Director of Liver Center

Beth Israel Deaconess Medical Center

Boston, Massachusetts

Fred Poordad, MD

Chief, Hepatology

Cedars-Sinai Medical Center

Associate Professor of Medicine

Geffen School of Medicine at UCLA

Los Angeles, California

K. Rajender Reddy, MD

Professor of Medicine,

Director of Hepatology,

Medical Director of Liver Transplantation

University of Pennsylvania School of Medicine

Philadelphia, Pennsylvania

Learning Objectives:

After completing this activity, the participant should be able to:

•

Implement appropriate monitoring and testing;

•

Explain and use, in a clinical setting, the key new studies on chronic hepatitis

C management and treatment presented at the 46th EASL;

•

Apply treatment paradigms for chronic hepatitis C;

•

Discuss with patients the studies and data on newer therapies for chronic

hepatitis C presented at the 46th EASL;

•

Apply information on newer therapies in therapeutic discussions.

Target Audience:

This activity is intended for physicians, physician assistants, advanced

practice nurses, and other health care professionals involved in the treatment

and management of patients with HCV infection.

Accreditation Statement:

This activity has been planned and implemented in accordance with the Essential

Areas and policies of the Accreditation Council for Continuing Medical Education

through the joint sponsorship of the Postgraduate Institute for Medicine and

ViralEd, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME

to provide continuing medical education for physicians.

Credit Designation:

The Postgraduate Institute for Medicine designates this live activity for a

maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim the

credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest:

Postgraduate Institute for Medicine (PIM) requires instructors, planners,

managers and other individuals who are in a position to control the content of

this activity to disclose any real or apparent conflict of interest they may

have as related to the content of this activity. All identified conflicts of

interest are thoroughly vetted by PIM for fair balance, scientific objectivity

of studies mentioned in the materials or used as the basis for content, and

appropriateness of patient care recommendations.

Supported by an educational grant from Merck & Co., Inc.

This coverage is not sanctioned by the conference organizers and

is not an official part of the conference proceedings

Forward email

This email was sent to shereemartin@... by editor@... |

Update Profile/Email Address | Instant removal with SafeUnsubscribe™ | Privacy

Policy.

HIVandHepatitis.com | 584 Castro Street #272 | San Francisco | CA | 94114